Crowd-sourced BiotechDueDiligence Journal Watch (June 2015)

Once again, I let the Twitterverse do the heavy lifting. Check out the recent notable papers from the scientific and medical literature that are driving the biotech, pharmaceuticals, drug development and healthcare discussions on Twitter and elsewhere.


Previous editions of the "Journal Watch"

Re CRISPR: @eric_lander makes a solid case for clinical caution & a germline editing ban http://t.co/YxNqkBUQSE @NEJM pic.twitter.com/UQ6YV5pqYs

— Eric Topol (@EricTopol) June 3, 2015

IMPROVE-IT: Ezetimibe provided incremental LDL lowering when added to statin therapy and improved CV outcomes. http://t.co/CJtqs0KINB

— NEJM (@NEJM) June 3, 2015

MT @neilfws: Nature "debating" whether social media appropriate for science discussion; rest of us are just doing it http://t.co/IH0RctBvW1

— Dale Yuzuki (@DaleYuzuki) May 21, 2015

Emerging approaches to address the ion channel abnormalities in #CysticFibrosis. http://t.co/3ZIlhagNGi #CFawareness pic.twitter.com/9kDmNk5h7g

— NatRevDiseasePrimers (@DiseasePrimers) May 15, 2015

Why you should stop using bar charts in small-sample data sets http://t.co/KcKA2o5d9d pic.twitter.com/volk3TSoD8 via @StuartJRitchie

— Andy Biotech (@AndyBiotech) May 3, 2015

I was going to write a blog post about this paper, but I don't think I can do a better job than this: https://t.co/Hbj9G6nrLa

— Dan Marks (@Festivus159) June 10, 2015

Decent (free) top-level, basic review of the immunotherapy space and potential therapeutic combinations for oncology. http://t.co/HrndZLHsZI

— David Miller (@AlpineBV_Miller) June 9, 2015

Study claims $28B a year spent on irreproducible biomedical research http://t.co/D3KwWsIzSu http://t.co/C0tAxekcyq pic.twitter.com/VXG94PndOW

— Andy Biotech (@AndyBiotech) June 10, 2015